Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRSTMAPPP trial of sunitinib versus placebo in malignant progressive pheochromocytoma/paraganglioma
NL-OMON37272Phase 2Recruiting
- Sponsor
- Gustave Roussy
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in pheochromocytoma and malignant paraganglioma comparing Sunitinib with Placebo (2 arms). Primary endpoint: Progression-free survival at 12 months. Started Sep 2013; status: recruiting.
02
Drugs
sunitinib
03
Conditions
pheochromocytomamalignant paraganglioma
Beyond the preview
Go deeper on NL-OMON37272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37272.